Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy

Official record

Identifier

NCT07851363

Recruiting locations

country

China

Interventions studied

HD-MTX-based chemotherapyBTK inhibitor

Lead sponsor

Xiaohui Ren

Target enrolment

300 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Recruiting

First posted

Oct 1, 2026

Last updated on the registry

Oct 1, 2026

Age

18 Years – 75 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Patients with pathologically confirmed primary central nervous system lymphoma;
* Lesions confined to the central nervous system (cerebral parenchyma, meninges, spinal cord or intraocular), with no evidence of systemic lymphoma;
* Aged ≥ 18 years and ≤ 75 years, no restriction on gender;
* Expected survival of more than 3 months;
* The subjects voluntarily join this study, understand the trial procedures and contents, sign the informed consent form, have good compliance and cooperate with follow-up.

Exclusion Criteria:

* Other types of central nervous system tumors;
* Without pathological confirmation basis;
* Patients complicated with other malignant tumors;
* Other conditions that are considered by the investigators to be unsuitable for participating in this trial.

Indexed under

Lymphoma